• Part I: Scientific and product-related information (e.g., protocol, IMPD)
• Part II: Country-specific documentation, including consent forms and recruitment materials

Language requirements primarily impact Part II, as this section includes patient-facing documents, investigator CVs, and site-level administrative details that must be presented in the national language.

For multinational trials, this means sponsors must prepare multiple language versions of several key documents, depending on the target countries.

Common Documents Requiring Translation

While scientific documents in Part I may be accepted in English by many Member States, the following Part II documents typically require translation:

• Informed Consent Form (ICF)
• Patient Information Sheet (PIS)
• Assent forms for minors
• Recruitment advertisements
• Lay summaries and trial results summaries
• Investigator CVs (in some countries)

Ethics committees review these documents to ensure participants understand the trial’s purpose, risks, and procedures. Therefore, translation accuracy is paramount.

Member State Language Rules, Translation Strategy, and Compliance

Member State Language Requirements

Each EU Member State defines its own acceptable languages for CTA documents. Some accept English for protocol-related materials but mandate local languages for participant documents. Here’s a simplified overview:

Country	Official Language(s)	ICF Language Requirement	Accept English for Protocol?
France	French	French only	No
Germany	German	German	Sometimes
Belgium	Dutch, French, German	By site region	Yes
Spain	Spanish	Spanish	No
Sweden	Swedish	Swedish	Yes

Sponsors must check the EU Clinical Trials Register or national competent authority (NCA) websites for up-to-date requirements.

Best Practices for Translation and Quality Assurance

To ensure translations meet regulatory and ethical standards:

• Use certified medical translators with native fluency
• Perform back-translation for critical materials like ICFs
• Review translated documents with local investigators
• Align terminology with regulatory and medical dictionaries
• Format translated documents consistently with originals

Some countries (e.g., Italy, Hungary) require notarized translations or formal translator declarations as part of ethics committee submission.

Translation Challenges and Risk Mitigation

Translation errors can delay approvals or lead to regulatory queries. Common pitfalls include:

• Inaccurate risk/benefit explanations
• Omission of mandatory clauses
• Ambiguities in consent-related content
• Mismatched terminology between protocol and ICF

Sponsors should maintain a language validation tracker and assign a language lead in the CTA submission team.

CTIS Submission and Language Mapping

When submitting via CTIS, sponsors must upload language-specific versions under the appropriate country tab in Part II. CTIS allows tagging documents by language and country to facilitate validation.

Sponsors must also ensure lay summaries of results are submitted in the same languages used for ICFs, as required under Article 37 of the EU CTR.

Case Example: Multinational Trial Across Five EU Countries

A sponsor conducting a Phase III vaccine trial in France, Belgium, Germany, Italy, and Sweden needs:

• ICF in French, Dutch, German, Italian, and Swedish
• PIS in same five languages
• Lay summary post-trial in five languages
• Protocol and IB possibly in English, depending on NCA preference

Translation planning must begin early and align with the Part II submission calendar in CTIS to avoid delays.

Conclusion: Language Compliance Is Critical to EU Trial Success

In the European Union, ensuring participants receive fully understandable information in their native language is both an ethical obligation and a regulatory requirement. Noncompliance can result in ethics rejection, NCA queries, or trial suspension.

Sponsors should develop a robust language strategy that includes expert translation, regional language mapping, and version control across CTIS submissions. With thoughtful planning, language need not be a barrier—but a bridge to ethical, inclusive, and regulatory-compliant clinical research.